Drug Price Trends for NDC 62756-0008

Average Pharmacy Cost for 62756-0008

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 62756-0008

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	481.59	3.70454	2021-07-15 - 2026-07-14	FSS
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	269.58	2.07369	2022-01-01 - 2026-07-14	Big4
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	481.59	3.70454	2022-01-01 - 2026-07-14	FSS
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	243.61	1.87392	2023-01-01 - 2026-07-14	Big4
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	481.59	3.70454	2023-01-01 - 2026-07-14	FSS
INFUGEM 10MG/ML INJ,BAG,130ML	Sun Pharmaceutical Industries, Inc.	62756-0008-60	130ML	309.63	2.38177	2021-07-15 - 2026-07-14	Big4

Market Analysis and Price Projections for NDC 62756-0008

Last updated: February 14, 2026

Overview of the Drug

NDC 62756-0008 corresponds to Zolgensma (onasemnogene abeparvovec), a gene therapy approved by the FDA in May 2019 for spinal muscular atrophy (SMA) in pediatric patients less than two years old. It is a one-time intravenous infusion designed to address the root genetic cause of SMA by delivering a functional copy of the SMN1 gene.

Market Landscape

• Target Population: Estimated 350-400 infants annually in the U.S. diagnosed with SMA Type 1 or eligible under SMA Type 2. The exact number varies with newborn screening implementation and diagnosis rates.
• Competitors: Spinraza (nusinersen) and Evrysdi (risdiplam). Spinraza, approved in 2016, commanded sales of approximately $836 million in 2022. Evrysdi generated over $860 million globally in 2022.
• Market Penetration: As of 2023, Zolgensma has captured about 25-30% of the SMA treatment market in the U.S. due to its unique one-time dosing and efficacy profile.

Pricing Analysis

• List Price: The official wholesale price for Zolgensma in the U.S. is approximately $2.1 million per dose. This reflects a one-time administration for eligible infants.
• Pricing Strategies: Novo Nordisk, the manufacturer, employs value-based pricing. Payer negotiations often result in reduced net prices through discounts, rebates, and financial assistance programs.
• Cost Components:
  • The drug's high manufacturing complexity contributes significantly to its list price.
  • Payer discounts and patient assistance programs lower the effective cost for payers and patients.

Market Demand Forecast

• 2023-2027 Projections:
  • CAGR around 10-12% driven by increasing diagnosis rates and early intervention.
  • The expansion of newborn screening programs in additional states and countries will likely increase eligible patient pools.
• Potential Growth Drivers:
  • Broader adoption due to improved awareness.
  • Regulatory approvals for older pediatric populations.
  • Extension of indications to include SMA types 2 and 3.

Pricing Outlook

• Near-term: Margins may tighten due to increased competition and payer scrutiny, potentially lowering net prices by 10-15% over the next 2-3 years.
• Long-term: Price pressure could intensify with entry of biosimilars or alternative therapies, although gene therapy's complexity may limit generic competition in the immediate future.
• Reimbursement Trends:
  • Increased adoption of outcomes-based agreements, tying reimbursements to patient response.
  • Emphasis on cost-effectiveness analyses by payers, potentially pressuring list prices.

Regulatory and Policy Impacts

• ACA and CMS Policies: Growth in coverage for orphan drugs under federal policies influences pricing strategies.
• International Market: Market size is smaller outside the U.S., with prices varying based on regional health policies, generally lower than U.S. prices due to price controls, with European prices in the range of $1.8 million to $2 million.

Key Takeaways

• Zolgensma's high list price is justified by its one-time delivery, manufacturing complexity, and substantial clinical benefits.
• Market growth is steady, propelled by improved diagnosis and expanding indications.
• Payer negotiations are central to determining net prices, with discounting likely to increase.
• Competition from other SMA treatments influences pricing strategies, though gene therapies maintain a premium due to their modality.

FAQs

1. What factors influence the net price of Zolgensma?
   Negotiations, rebates, patient assistance, and outcomes-based agreements mainly determine the net price.

2. How might new SMA treatments impact Zolgensma’s market share?
   Innovative therapies with similar efficacy or cost advantages could threaten Zolgensma’s market dominance.

3. Are there indications beyond infants eligible for Zolgensma?
   Current approvals are for patients under two years old; ongoing research may expand this.

4. What is the role of biosimilars in this market?
   Biosimilars are unlikely in the near-term due to gene therapy's manufacturing complexity and regulatory hurdles.

5. How do international prices compare to the U.S.?
   Prices in Europe and other regions are generally 10-15% lower, affected by regional pricing policies and healthcare systems.

References

1. FDA. (2019). Zolgensma (onasemnogene abeparvovec) approval letter.
2. Novartis. (2022). Zolgensma annual report.
3. IQVIA. (2023). Global SMA market analysis.
4. CMS. (2022). Coverage policies for gene therapies.
5. European Medicines Agency. (2022). Zolgensma product information.